Investment Rating - The investment rating for the company is "Accumulate" and is maintained [6]. Core Views - The company reported a revenue of 1.3 billion yuan for Q1-Q3 2025, a year-on-year decline of 11.5%, and a net profit attributable to shareholders of 330 million yuan, down 36.7% year-on-year. In Q3 alone, revenue was 430 million yuan, a decrease of 17.6%, with a net profit of 95.39 million yuan, down 45% year-on-year [2][4][10]. - The decline in performance is attributed to several factors, including a drop in gross margin by 1.7 percentage points to 80.4%, an increase in sales expense ratio by 10 percentage points to 46.3%, and a rise in management expense ratio by 2 percentage points to 5.4% [10]. - The company is focusing on balanced development between medical devices and functional skincare products, launching various new products to meet consumer demand. It is also enhancing its channel management and support systems to improve operational efficiency and profitability [10]. Financial Performance - For the fiscal year 2025, the company expects earnings per share (EPS) to be 0.83 yuan, 0.89 yuan, and 0.94 yuan for the years 2025, 2026, and 2027 respectively [10]. - The projected total revenue for 2025 is estimated at 2.017 billion yuan, with a net profit of 429 million yuan [15]. - The company’s net profit margin is projected to stabilize, supported by core product repurchase and the gradual establishment of e-commerce channel methodologies [10].

Core Viewpoint - The functional skincare industry in China is experiencing a rise of domestic brands, with products categorized into three main segments: dermatological skincare, high-efficacy skincare, and medical aesthetic skincare [1][2]. Group 1: Industry Overview - Functional skincare products are designed to alleviate or assist in treating specific skin issues, classified as either cosmetic (妆字号) or medical devices (械字号) [1]. - The industry is characterized by a growing presence of domestic brands, indicating a shift in market dynamics [1]. Group 2: Market Segmentation - The functional skincare market is divided into three segments: - Dermatological skincare, typically developed by cosmetic companies in collaboration with dermatologists, includes brands like Winona and La Roche-Posay [2]. - High-efficacy skincare, which emphasizes chemical ingredients, features brands such as WIS and HFP [2]. - Medical aesthetic skincare, developed by companies with a background in biomedicine or medical devices, includes brands like Fulejia and Kefu Mei [2]. Group 3: Product Composition - Dermatological skincare products focus on simplified and targeted ingredients, with examples like Winona's "Soothing Moisturizing Cream" containing ingredients such as sea buckthorn and hyaluronic acid [4]. - High-efficacy skincare products highlight active ingredients like niacinamide and salicylic acid [4]. - Medical aesthetic skincare products, such as those from Chuangfukang, contain fewer ingredients, focusing on essential components like collagen [4]. Group 4: Company Product Strategies - Companies in the functional skincare sector are diversifying their product lines, with many offering both cosmetic and medical device products [6]. - For instance, Betaini focuses on dermatological skincare while also extending into medical device products [6]. Group 5: Company Registration Data - Various companies have registered a significant number of products under both cosmetic and medical device categories, indicating a robust presence in the market: - Huaxi Biological has 1,766 cosmetic registrations and 27 medical device registrations [7]. - Fulejia has 3 cosmetic registrations and 110 medical device registrations [7].

Core Insights - Harbin Fulejia Technology Co., Ltd. is actively adjusting its business strategy in response to market changes, with a focus on increasing R&D investment and maintaining stable dividends for long-term growth [2] Financial Performance - For the first half of 2025, the company reported a total revenue of 863 million yuan, with a second-quarter revenue of 562 million yuan, reflecting a year-on-year growth of 5.9% [2] - The net profit attributable to shareholders for the first half of the year was 230 million yuan, and the net cash flow from operating activities was 162 million yuan, indicating stable cash flow [2] - As of the end of the reporting period, total assets reached 5.699 billion yuan, and net assets attributable to shareholders were 5.492 billion yuan, maintaining a robust financial structure [2] R&D and Product Development - R&D investment increased by 47.65% year-on-year to 23.33 million yuan, with the R&D team expanding by 18.97% to 69 personnel [4] - The company has been granted a total of 31 patents, including 9 invention patents, and has established a comprehensive intellectual property protection system [4] - The gross profit margin for medical device products was 84.22%, while for cosmetics, it was 80.42%, indicating strong profitability [4] Sales and Marketing - Sales expenses for the first half of 2025 were 420 million yuan, a year-on-year increase of 39.56%, primarily due to higher personnel salaries and increased promotional spending [5] - The company optimized its sales structure to enhance operational efficiency, which contributed to the improvement of overall revenue structure [5] Market Position and Strategy - The cosmetics segment showed strong resilience, with revenue increasing by 29.95% to 625 million yuan, accounting for 72.39% of total revenue [3] - The company is focusing on expanding its product matrix, including new launches such as medical sodium hyaluronate repair liquid and collagen anti-wrinkle essence [4] - Fulejia aims to strengthen its core competitiveness through dual R&D centers in Harbin and Shanghai, focusing on innovative raw material development and accelerating technology transfer [6]

Core Viewpoint - The functional skincare industry in China is experiencing a rise of domestic brands, with various listed companies involved across the supply chain, including raw materials, packaging, and sales channels [1][2]. Group 1: Industry Overview - Functional skincare products are designed to address specific skin issues and possess certain pharmacological effects, indicating a growing market for targeted skincare solutions [1]. - The industry is characterized by a diverse range of companies, from raw material suppliers to online and offline sales channels [2]. Group 2: Company Distribution - Key companies in the raw materials segment include Kesheng Co., Qingsong Co., and Xinhang New Materials, while packaging material companies include Jiaheng Household and Jinsong New Materials [2][3]. - Major players in the functional skincare segment include Betaini, Huaxi Biological, Shanghai Jahwa, and Chuang'er Biological, with significant online sales channels represented by Alibaba, JD.com, and Pinduoduo [2][4]. Group 3: Financial Performance - Betaini leads the industry with a revenue of 57.36 billion yuan in 2024, followed by Huaxi Biological with 53.71 billion yuan and Shanghai Jahwa with 56.79 billion yuan [6][18]. - The gross profit margins for most companies in the functional skincare sector range from 70% to 85%, with Juzhi Biological achieving the highest margin at 82.09% [17][18]. Group 4: Business Strategies - Companies are focusing on R&D innovation, brand enhancement, and channel optimization to capture more market share and adapt to competitive pressures [19]. - Betaini plans to enhance its product offerings in the baby skincare segment and expand its online and offline presence, while Huaxi Biological is shifting towards anti-aging strategies and enhancing its technological capabilities [20][19]. Group 5: Market Positioning - Betaini has a dominant market position with 99.49% of its business in functional skincare, primarily targeting the Chinese market [16]. - Huaxi Biological and Shanghai Jahwa have also established strong brand identities with competitive product lines, while Chuang'er Biological focuses on collagen products [14][16].